Advertisement

Current Heart Failure Reports

, Volume 15, Issue 4, pp 270–279 | Cite as

Pharmacologic Management of Cancer Therapeutics-Induced Cardiomyopathy in Adult Cancer Survivors

  • J. Emanuel Finet
  • Gregory A. Wiggers
Pharmacologic Therapy (W Tang, Section Editor)
  • 113 Downloads
Part of the following topical collections:
  1. Topical Collection on Pharmacologic Therapy

Abstract

Purpose of Review

The number of cancer survivors is exponentially increasing worldwide, due to both advances in cancer detection and treatment strategies, as well as the aging and growth of the population. This decrease in cancer mortality has brought forth a concurrent increase of non-ischemic (toxic) dilated cardiomyopathy in the survivor population, also known as cancer therapeutics-induced cardiomyopathy (CTIC). The optimal pharmacological management for this condition is still elusive, and hence, the focus of this work.

Recent Findings

Our review of the literature did not identify any prospective randomized clinical trial of CTIC in adult cancer survivors, neither published nor in progress. However, available data seem to suggest that, when managed with standard guideline-derived medical therapy, the outcomes of CTIC are comparable to that of idiopathic dilated cardiomyopathy (IDC). Nonetheless, the evidence behind this strategy is inadequate.

Summary

Until new information becomes available, pharmacological management of CTIC must parallel that of IDC. However, implementation of such may be hindered by other cancer therapeutics-induced comorbidities and conditioned by the particular effects of heart failure pharmacotherapy on cancer outcomes. This work succinctly reviews these three areas, in the context of adult cancer survivors.

Keywords

Heart failure Cancer survivors Cardiotoxicity Cancer therapies Cardiomyopathy Heart failure pharmacotherapy 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. 1.
    • Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.  https://doi.org/10.3322/caac.21349. This article describes the latest cancer treatment and survivorship statistics. CrossRefPubMedGoogle Scholar
  2. 2.
    ashakkor AY, Moghaddamjou A, Chen L, Cheung WY. Predicting the risk of cardiovascular comorbidities in adult cancer survivors. Curr Oncol. 2013;20(5):e360–70.  https://doi.org/10.3747/co.20.1470.
  3. 3.
    •• Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;  https://doi.org/10.1093/eurheartj/ehw211. This ESC position article summarizes the most current epidemiology, pathophysiology, and prevention and therapeutic strategies of common cardiovascular complications of cancer therapies.
  4. 4.
    Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–82.  https://doi.org/10.1056/NEJMsa060185.CrossRefPubMedGoogle Scholar
  5. 5.
    • Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–911.  https://doi.org/10.1200/JCO.2016.70.5400. This work brings together cardiologists and oncologists to define prevention and monitoring strategies of cardiac dysfunction in cancer survivors. CrossRefPubMedGoogle Scholar
  6. 6.
    • Finet JE. Management of heart failure in cancer patients and cancer survivors. Heart Fail Clin. 2017;13(2):253–88.  https://doi.org/10.1016/j.hfc.2016.12.004. This work summarizes the current management guidelines of HF syndromes in cancer patients and cancer survivors. CrossRefPubMedGoogle Scholar
  7. 7.
    Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol. 1998;27(1):53–68.CrossRefPubMedGoogle Scholar
  8. 8.
    Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8.  https://doi.org/10.1161/CIRCULATIONAHA.114.013777.CrossRefPubMedGoogle Scholar
  9. 9.
    Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474–81.  https://doi.org/10.1161/CIRCULATIONAHA.106.635144.CrossRefPubMedGoogle Scholar
  10. 10.
    Armenian SH, Mertens L, Slorach C, Venkataraman K, Mascarenhas K, Nathwani N, et al. Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. Cancer. 2017;124:850–7.  https://doi.org/10.1002/cncr.31110.CrossRefPubMedGoogle Scholar
  11. 11.
    Temming P, Qureshi A, Hardt J, Leiper AD, Levitt G, Ancliff PJ, et al. Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom. Pediatr Blood Cancer. 2011;56(4):625–30.  https://doi.org/10.1002/pbc.22908.CrossRefPubMedGoogle Scholar
  12. 12.
    Oliveira GH, Hardaway BW, Kucheryavaya AY, Stehlik J, Edwards LB, Taylor DO. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. J Heart Lung Transplant. 2012;31(8):805–10.  https://doi.org/10.1016/j.healun.2012.03.018. CrossRefPubMedGoogle Scholar
  13. 13.
    Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077–84.  https://doi.org/10.1056/NEJM200004133421502.CrossRefPubMedGoogle Scholar
  14. 14.
    Tallaj JA, Franco V, Rayburn BK, Pinderski L, Benza RL, Pamboukian S, et al. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005;24(12):2196–201.  https://doi.org/10.1016/j.healun.2004.12.108. CrossRefPubMedGoogle Scholar
  15. 15.
    Fornaro A, Olivotto I, Rigacci L, Ciaccheri M, Tomberli B, Ferrantini C, et al. Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience. Eur J Heart Fail. 2017;20:898–906.  https://doi.org/10.1002/ejhf.1049.CrossRefPubMedGoogle Scholar
  16. 16.
    Rickard J, Kumbhani DJ, Baranowski B, Martin DO, Tang WH, Wilkoff BL. Usefulness of cardiac resynchronization therapy in patients with Adriamycin-induced cardiomyopathy. Am J Cardiol. 2010;105(4):522–6.  https://doi.org/10.1016/j.amjcard.2009.10.024.CrossRefPubMedGoogle Scholar
  17. 17.
    Oliveira GH, Dupont M, Naftel D, Myers SL, Yuan Y, Tang WH, et al. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63(3):240–8.  https://doi.org/10.1016/j.jacc.2013.09.040. CrossRefPubMedGoogle Scholar
  18. 18.
    •• Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–327.  https://doi.org/10.1161/CIR.0b013e31829e8776. Most current AHA/ACC guidelines on the evaluation and management of Heart Failure. CrossRefPubMedGoogle Scholar
  19. 19.
    •• Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776–803.  https://doi.org/10.1016/j.jacc.2017.04.025. Most current update to the 2013 HF guidelines; sponsored by ACC, AHA, and HFSA. CrossRefPubMedGoogle Scholar
  20. 20.
    Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22(5):820–8.  https://doi.org/10.1200/JCO.2004.06.022.CrossRefPubMedGoogle Scholar
  21. 21.
    Cheuk DK, Sieswerda E, van Dalen EC, Postma A, Kremer LC. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst Rev. 2016;8:CD008011.  https://doi.org/10.1002/14651858.CD008011.pub3.CrossRefGoogle Scholar
  22. 22.
    The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised Trials Lancet 1999;353(9146):9–13.Google Scholar
  23. 23.
    Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001–7.CrossRefGoogle Scholar
  24. 24.
    Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13.  https://doi.org/10.1016/S0140-6736(03)13800-7.CrossRefPubMedGoogle Scholar
  26. 26.
    Group CTS. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian Enalapril survival study (CONSENSUS). N Engl J Med. 1987;316(23):1429–35.  https://doi.org/10.1056/NEJM198706043162301. CrossRefGoogle Scholar
  27. 27.
    Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.  https://doi.org/10.1056/NEJM199108013250501.CrossRefGoogle Scholar
  28. 28.
    Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303–10.  https://doi.org/10.1056/NEJM199108013250502.CrossRefPubMedGoogle Scholar
  29. 29.
    Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med. 1992;327(10):669–77.  https://doi.org/10.1056/NEJM199209033271001. CrossRefPubMedGoogle Scholar
  30. 30.
    Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100(23):2312–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Cohn JN, Tognoni G. Valsartan heart failure trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667–75.  https://doi.org/10.1056/NEJMoa010713. CrossRefPubMedGoogle Scholar
  32. 32.
    Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet. 2003;362(9386):772–6.  https://doi.org/10.1016/S0140-6736(03)14284-5.CrossRefPubMedGoogle Scholar
  33. 33.
    Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–906.  https://doi.org/10.1056/NEJMoa032292.CrossRefPubMedGoogle Scholar
  34. 34.
    McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet. 2003;362(9386):767–71.  https://doi.org/10.1016/S0140-6736(03)14283-3.CrossRefPubMedGoogle Scholar
  35. 35.
    Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374(9704):1840–8.  https://doi.org/10.1016/S0140-6736(09)61913-9.CrossRefPubMedGoogle Scholar
  36. 36.
    McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.  https://doi.org/10.1056/NEJMoa1409077.CrossRefPubMedGoogle Scholar
  37. 37.
    McMurray JJ, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, et al. Aliskiren, Enalapril, or Aliskiren and Enalapril in heart failure. N Engl J Med. 2016;374(16):1521–32.  https://doi.org/10.1056/NEJMoa1514859.CrossRefPubMedGoogle Scholar
  38. 38.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.  https://doi.org/10.1056/NEJM199909023411001. CrossRefPubMedGoogle Scholar
  39. 39.
    Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.  https://doi.org/10.1056/NEJMoa1009492.CrossRefPubMedGoogle Scholar
  40. 40.
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.  https://doi.org/10.1056/NEJMoa030207.CrossRefPubMedGoogle Scholar
  41. 41.
    Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a veterans administration cooperative study. N Engl J Med. 1986;314(24):1547–52.  https://doi.org/10.1056/NEJM198606123142404. CrossRefPubMedGoogle Scholar
  42. 42.
    Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049–57.  https://doi.org/10.1056/NEJMoa042934.CrossRefPubMedGoogle Scholar
  43. 43.
    Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective randomized amlodipine survival evaluation study group. N Engl J Med. 1996;335(15):1107–14.  https://doi.org/10.1056/NEJM199610103351504. CrossRefPubMedGoogle Scholar
  44. 44.
    Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O'Connor C, et al. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). JACC Heart Fail. 2013;1(4):308–14.  https://doi.org/10.1016/j.jchf.2013.04.004. CrossRefPubMedGoogle Scholar
  45. 45.
    Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–85.  https://doi.org/10.1016/S0140-6736(10)61198-1.CrossRefPubMedGoogle Scholar
  46. 46.
    Digitalis Investigation G. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–33.  https://doi.org/10.1056/NEJM199702203360801.CrossRefGoogle Scholar
  47. 47.
    Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248–61.  https://doi.org/10.1056/NEJMoa0706201.CrossRefPubMedGoogle Scholar
  48. 48.
    Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231–9.  https://doi.org/10.1016/S0140-6736(08)61240-4.CrossRefPubMedGoogle Scholar
  49. 49.
    Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223–30.  https://doi.org/10.1016/S0140-6736(08)61239-8.CrossRefPubMedGoogle Scholar
  50. 50.
    Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436–48.  https://doi.org/10.1056/NEJMoa0908355.CrossRefPubMedGoogle Scholar
  51. 51.
    Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J. 2015;36(11):657–68.  https://doi.org/10.1093/eurheartj/ehu385.CrossRefPubMedGoogle Scholar
  52. 52.
    van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Bohm M, Doletsky A, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136(15):1374–83.  https://doi.org/10.1161/CIRCULATIONAHA.117.027497.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA. 2017;317(19):1958–66.  https://doi.org/10.1001/jama.2017.5427.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013;368(13):1210–9.  https://doi.org/10.1056/NEJMoa1214865.CrossRefPubMedGoogle Scholar
  55. 55.
    Frohlich H, Torres L, Tager T, Schellberg D, Corletto A, Kazmi S, et al. Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. Clin Res Cardiol. 2017;106(9):711–21.  https://doi.org/10.1007/s00392-017-1115-0.CrossRefPubMedGoogle Scholar
  56. 56.
    Fiuzat M, Wojdyla D, Pina I, Adams K, Whellan D, O'Connor CM. Heart rate or Beta-blocker dose? Association with outcomes in ambulatory heart failure patients with systolic dysfunction: Results From the HF-ACTION Trial. JACC Heart Fail. 2016;4(2):109–15.  https://doi.org/10.1016/j.jchf.2015.09.002.CrossRefPubMedGoogle Scholar
  57. 57.
    Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258–62.  https://doi.org/10.1016/j.jacc.2006.07.052.CrossRefPubMedGoogle Scholar
  58. 58.
    Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355–62.  https://doi.org/10.1016/j.jacc.2013.02.072. CrossRefPubMedGoogle Scholar
  59. 59.
    Pituskin E, Haykowsky M, Mackey JR, Thompson RB, Ezekowitz J, Koshman S, et al. Rationale and design of the multidisciplinary approach to novel therapies in cardiology oncology research trial (MANTICORE 101—breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer. 2011;11:318.  https://doi.org/10.1186/1471-2407-11-318.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671–80.  https://doi.org/10.1093/eurheartj/ehw022.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    • Payne DL, Nohria A. Prevention of chemotherapy induced cardiomyopathy. Current Heart Fail Rep. 2017;14(5):398–403.  https://doi.org/10.1007/s11897-017-0353-9. This work summarizes the most current clinical trials on CTIC prevention. CrossRefGoogle Scholar
  62. 62.
    Khan MS, Fonarow GC, Ahmed A, Greene SJ, Vaduganathan M, Khan H, et al. Dose of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and outcomes in heart failure: a meta-analysis. Circ Heart Fail. 2017;10(8):e003956.  https://doi.org/10.1161/CIRCHEARTFAILURE.117.003956.CrossRefPubMedGoogle Scholar
  63. 63.
    Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015;17(1):81–9.  https://doi.org/10.1002/ejhf.196.CrossRefPubMedGoogle Scholar
  64. 64.
    Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, et al. Angiotensin II-receptor inhibition with candesartan to prevent Trastuzumab-related Cardiotoxic effects in patients with early breast Cancer: a randomized clinical trial. JAMA Oncol. 2016;2(8):1030–7.  https://doi.org/10.1001/jamaoncol.2016.1726.CrossRefPubMedGoogle Scholar
  65. 65.
    Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of Trastuzumab-associated Cardiotoxicity. J Clin Oncol. 2017;35(8):870–7.  https://doi.org/10.1200/JCO.2016.68.7830.CrossRefPubMedGoogle Scholar
  66. 66.
    Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54–61.  https://doi.org/10.1161/CIRCULATIONAHA.114.013748.CrossRefPubMedGoogle Scholar
  67. 67.
    Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, et al. Influence of ejection fraction on outcomes and efficacy of Sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circ Heart Fail. 2016;9(3):e002744.  https://doi.org/10.1161/CIRCHEARTFAILURE.115.002744.CrossRefPubMedGoogle Scholar
  68. 68.
    Ibrahim NE, Januzzi JL, Rabideau DJ, Gandhi PU, Gaggin HK. Serial heart rates, guideline-directed beta blocker use, and outcomes in patients with chronic heart failure with reduced ejection fraction. Am J Cardiol. 2017;120(5):803–8.  https://doi.org/10.1016/j.amjcard.2017.05.052.CrossRefPubMedGoogle Scholar
  69. 69.
    Komajda M, Tavazzi L, Swedberg K, Bohm M, Borer JS, Moyne A, et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. Eur J Heart Fail. 2016;18(9):1182–9.  https://doi.org/10.1002/ejhf.582.CrossRefPubMedGoogle Scholar
  70. 70.
    Upshaw JN, van Klaveren D, Konstam MA, Kent DM. Digoxin benefit varies by risk of heart failure hospitalization: applying the Tufts MC HF risk model. Am J Med. 2018;2017  https://doi.org/10.1016/j.amjmed.2017.12.010.
  71. 71.
    Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015;36(28):1831–8.  https://doi.org/10.1093/eurheartj/ehv143.CrossRefPubMedGoogle Scholar
  72. 72.
    Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58(9):988–9.  https://doi.org/10.1016/j.jacc.2011.05.025.CrossRefPubMedGoogle Scholar
  73. 73.
    Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60(23):2384–90.  https://doi.org/10.1016/j.jacc.2012.07.067.CrossRefPubMedGoogle Scholar
  74. 74.
    Chotenimitkhun R, D'Agostino R Jr, Lawrence JA, Hamilton CA, Jordan JH, Vasu S, et al. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. Can J Cardiol. 2015;31(3):302–7.  https://doi.org/10.1016/j.cjca.2014.11.020. CrossRefPubMedGoogle Scholar
  75. 75.
    Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575–82 e3.  https://doi.org/10.1016/j.ahj.2013.01.017.CrossRefPubMedGoogle Scholar
  76. 76.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.  https://doi.org/10.1093/eurheartj/ehw128.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Paice JA, Portenoy R, Lacchetti C, Campbell T, Cheville A, Citron M, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(27):3325–45.  https://doi.org/10.1200/JCO.2016.68.5206.CrossRefPubMedGoogle Scholar
  78. 78.
    Zheng Z, Yabroff KR, Guy GP Jr, Han X, Li C, Banegas MP, et al. Annual medical expenditure and productivity loss among colorectal, female breast, and prostate cancer survivors in the United States. J Natl Cancer Inst. 2016;108(5):djv382.  https://doi.org/10.1093/jnci/djv382.CrossRefGoogle Scholar
  79. 79.
    • Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude lifetime cohort study (SJLIFE). Lancet. 2017;390(10112):2569–82.  https://doi.org/10.1016/S0140-6736(17)31610-0. This work describes the most common comorbidities of survivors of childhood cancers. CrossRefPubMedGoogle Scholar
  80. 80.
    Kattlove H, Winn RJ. Ongoing care of patients after primary treatment for their cancer. CA Cancer J Clin. 2003;53(3):172–96.CrossRefPubMedGoogle Scholar
  81. 81.
    Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11(7):627–36.  https://doi.org/10.1016/S1470-2045(10)70106-6.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12(1):65–82.  https://doi.org/10.1016/S1470-2045(10)70260-6.CrossRefPubMedGoogle Scholar
  83. 83.
    Collaboration ARBT. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011;29(4):623–35.  https://doi.org/10.1097/HJH.0b013e328344a7de.CrossRefGoogle Scholar
  84. 84.
    Pasternak B, Svanstrom H, Callreus T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011;123(16):1729–36.  https://doi.org/10.1161/CIRCULATIONAHA.110.007336.CrossRefPubMedGoogle Scholar
  85. 85.
    FDA Drug Saf Communication: No increase in risk of cancer with certain blood pressure drugs—angiotensive receptor blockers (ARBs) [06-02-2011] http://www.fda.gov/Drugs/DrugSafety/ucm257516.htm.
  86. 86.
    Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat. 2011;129(2):549–56.  https://doi.org/10.1007/s10549-011-1505-3.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Sipahi I, Chou J, Mishra P, Debanne SM, Simon DI, Fang JC. Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk. Am J Cardiol. 2011;108(2):294–301.  https://doi.org/10.1016/j.amjcard.2011.03.038.CrossRefPubMedGoogle Scholar
  88. 88.
    Ahern TP, Lash TL, Sorensen HT, Pedersen L. Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res. 2008;10(6):R102.  https://doi.org/10.1186/bcr2205.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Biggar RJ, Wohlfahrt J, Oudin A, Hjuler T, Melbye M. Digoxin use and the risk of breast cancer in women. J Clin Oncol. 2011;29(16):2165–70.  https://doi.org/10.1200/JCO.2010.32.8146.CrossRefPubMedGoogle Scholar
  90. 90.
    Osman MH, Farrag E, Selim M, Osman MS, Hasanine A, Selim A. Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies. PLoS One. 2017;12(6):e0178611.  https://doi.org/10.1371/journal.pone.0178611.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Mackenzie IS, Macdonald TM, Thompson A, Morant S, Wei L. Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. BMJ. 2012;345:e4447.  https://doi.org/10.1136/bmj.e4447.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Chuang YW, Yu MC, Huang ST, Yang CK, Chen CH, Lo YC, et al. Spironolactone and the risk of urinary tract cancer in patients with hypertension: a nationwide population-based retrospective case-control study. J Hypertens. 2017;35(1):170–7.  https://doi.org/10.1097/HJH.0000000000001130.CrossRefPubMedGoogle Scholar
  93. 93.
    Arnspang S, Gaist D, Johannesdottir Schmidt SA, Holmich LR, Friis S, Pottegard A. Hydrochlorothiazide use and risk of non-melanoma skin cancer: a nationwide case-control study from Denmark. J Am Acad Dermatol. 2017;  https://doi.org/10.1016/j.jaad.2017.11.042.
  94. 94.
    Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011;29(19):2645–52.  https://doi.org/10.1200/JCO.2010.33.4441.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Raimondi S, Botteri E, Munzone E, Cipolla C, Rotmensz N, DeCensi A, et al. Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: systematic review and meta-analysis. Int J Cancer. 2016;139(1):212–9.  https://doi.org/10.1002/ijc.30062. CrossRefPubMedGoogle Scholar
  96. 96.
    Grytli HH, Fagerland MW, Fossa SD, Tasken KA, Haheim LL. Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate. 2013;73(3):250–60.  https://doi.org/10.1002/pros.22564.CrossRefPubMedGoogle Scholar
  97. 97.
    Grytli HH, Fagerland MW, Fossa SD, Tasken KA. Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. 2014;65(3):635–41.  https://doi.org/10.1016/j.eururo.2013.01.007.CrossRefPubMedGoogle Scholar
  98. 98.
    Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28(9):1467–72.  https://doi.org/10.1200/JCO.2009.22.7918.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, Iwamoto T, et al. Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer. 2013;109(2):318–24.  https://doi.org/10.1038/bjc.2013.342.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Couttenier A, Lacroix O, Vaes E, Cardwell CR, De Schutter H, Robert A. Statin use is associated with improved survival in ovarian cancer: a retrospective population-based study. PLoS One. 2017;12(12):e0189233.  https://doi.org/10.1371/journal.pone.0189233.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Section of Heart Failure and Transplantation Medicine, Department of Cardiovascular MedicineCleveland ClinicClevelandUSA
  2. 2.Clinical EffectivenessWolters Kluwer HealthHudsonUSA

Personalised recommendations